Summary by Moomoo AI
BlackRock, Inc., a major investment management corporation based in Delaware, has filed an amended Schedule 13G with the Securities and Exchange Commission on January 26, 2024, indicating a 7.2% ownership stake in Cassava Sciences, a biopharmaceutical company. The filing, which reflects the state of ownership as of December 31, 2023, shows that BlackRock possesses sole voting power over 2,987,094 shares and sole dispositive power over 3,037,415 shares of Cassava Sciences' common stock. This amendment is a routine disclosure required by financial regulations for entities that have significant ownership in public companies. The filing also includes a list of entities under BlackRock that beneficially own 5% or greater of the outstanding shares of Cassava Sciences, as well as a power of attorney document detailing the authorization of certain individuals to act on behalf of BlackRock in fulfilling reporting requirements.